Biocon extends licensing pact with Equillium for itolizumab

Itolizumab, a first-in-class humanized anti-CD6 monoclonal antibody, is developed by Biocon and launched in 2013 in India under the brand name ALZUMAb to treat moderate to severe plaque psoriasis, a skin disease.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2PGSqdl
via IFTTT

0 comments:

Post a Comment